Women's health companies drew a record $1.55 billion in disclosed equity investment in 2025, up 41% from $1.1 billion in 2024, according to a recent report from W Group.
The report, the organization's first global women's health investment report, was built on proprietary tracking of more than 500 funding stories and around 164 equity rounds, and it reveals a sector at its largest-ever scale, with capital reaching more companies, categories and countries than at any point on record, according to W Group, a data-first intelligence platform.
Eighty-five companies raised equity in 2025, the highest single-year count ever recorded, and 10 rounds reached $50 million or more, double the number in 2024.
The report asserts that women's health has shifted from a market defined by a few breakout companies to one defined by a functioning, broad-based investment ecosystem. The report authors note that 2026 is the "era of scale."
"Women’s health is no longer an emerging category seeking validation. It is a functioning investment ecosystem entering its next phase. The Era of Scale is not a prediction. It is a description of what the data already shows—an invitation to build what it still requires," the report authors wrote.
But the report’s central finding is not the headline number. It is that the money has stopped concentrating at the top. In 2024, the three largest rounds accounted for 41% of all disclosed capital; in 2025 that share fell to 32%, as funding to companies outside the top three grew 56% year over year.
Two years ago, the top three rounds—Flo ($200 million), Maven ($125 million) and Amber ($100 million)—represented three categories that were all consumer-facing. The remaining 76 deals shared approximately $675 million between them, according to the report. In 2024, the five $50 million+ rounds were clustered in four categories—digital health platforms, pelvic/urinary devices, menopause and contraception.
However, in 2025, the lower concentration in the top three rounds meant that the remaining approximately 83 deals shared $1.05 billion. Also, the ten $50 million+ rounds were spread across seven categories, including oncology, fertility, maternal care, menopause, metabolic/GLP-1, sexual health diagnostics and cross-category digital health.
GLP-1 and metabolic health, effectively a non-existent funding category a year ago, arrived with a $50 million series A for SheMed.
Both endometriosis and women’s bone health attracted significant investment as well, with $57 million and $8 million, respectively.
Despite these funding efforts, women’s cardiovascular health and autoimmune disease remain essentially unfunded. Although significant capital is generally dedicated to these fields, there remains zero women-dedicated equity in these fields, reflecting a large capital gap for diseases that disproportionately affect women, the report noted.
There was a marked shift in geographic range as well, with Germany, Austria, Switzerland, Israel and the U.K. joining the U.S., with company profiles that are more biotech and clinically focused.
The capital deployers also changed in 2025, with 11 fundraisers emerging that address women’s health, including Nina Capital, Bread & Butter Ventures and GG Ventures. Pfizer also joined the conversation with a $35 million investment in Carrick Therapeutics, which focuses on breast/ovarian cancer cell therapy. Female celebrities also invested cultural capital in women’s health, with Meghan Markle and Emma Watson investing in Midi Health and Hertility, respectively.
The report also identifies a single structural risk: a series A bottleneck. While 35 to 40 companies raise pre-seed and seed rounds each year, only around 20 to 25 reach series A, and many companies that raised seed rounds in 2024 did not raise again in 2025.
Growth in women's health is concentrated in the series B stage, the report noted.
“More companies are reaching the growth stage. The question is whether exit pathways will be ready for them when they arrive,” the report authors said.
“2025 was the biggest year women’s health has ever had, and the most important finding isn’t the headline number. It’s that the money has stopped pooling at the top. Capital is reaching more companies, more categories and more countries than ever before,” Molly Taylor, head of content at W Group, said in a statement. “The Era of Scale is real. It’s just not finished, and the Series A gap is where it could stall. Closing that gap is the highest leverage move this ecosystem can make in 2026.”